Confusion surrounding Phase III data for a myelodysplastic syndrome candidate named Dacogen caused SuperGen Inc.'s stock to dive, despite the firm's contention that the data are positive.
Confusion surrounding Phase III data for a myelodysplastic syndrome candidate named Dacogen caused SuperGen Inc.'s stock to dive, despite the firm's contention that the data are positive.
